Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs CRISPR Therapeutics AG

A Tale of Two Biotech Giants: Gilead Sciences vs. CRISPR Therapeutics

In the ever-evolving world of biotechnology, cost efficiency is a critical metric for success. This chart compares the cost of revenue for Gilead Sciences, Inc. and CRISPR Therapeutics AG from 2014 to 2023. Gilead Sciences, a stalwart in the industry, consistently reported higher costs, peaking at approximately $6.6 billion in 2021. In contrast, CRISPR Therapeutics, a pioneer in gene editing, showed a more dynamic trend, with costs rising from a modest $1.5 million in 2014 to over $130 million in 2023.

Despite the disparity in absolute numbers, the growth rate of CRISPR's cost of revenue is noteworthy, increasing by over 8,500% over the decade. This reflects the company's rapid expansion and investment in cutting-edge technologies. Meanwhile, Gilead's costs grew by about 72%, indicating a more stable, mature business model. This comparison highlights the contrasting strategies of these biotech leaders in navigating the competitive landscape.